F3 and cancer: The elevated risk for thromboembolic events (TEE) in cancer in general is due to an increased coagulation activity by various mechanisms like the release of coagulation-stimulating factors and activators such as tissue factor or coagulation factors like factor VII and factor X as well as inflammatory cytokines by the cancer cells, which can lead to endothelial damage, dysfunction and induction of the coagulation cascade and platelet activity—as well as fibrinolysis-inhibiting substances such as plasminogen activator inhibitor 1 (PAI-1) [18].